Clinical trial · Observational
Chemotherapy-related Cognitive Impairment and Acute Leukemia
Chemotherapy-related Cognitive Impairment in Adults With Acute Leukemia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an ancillary study of an intervention study (NCT04570709). The parent study is a single institution, feasibility trial of 20 (10 control and 10 intervention) patients with the primary objective of assessing feasibility, acceptability, and change in pre and post measures of symptoms, function, and quality of life by administering the Palliative and Collaborative Care InTervention (PACT). We will further assess cognitive function in the patients who participate in the control of the parent study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| none (observational study) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Control group of the LCCC1848
- description
- Patients in the control arm will receive standard of care.
- interventionNames
- Other: none (observational study)
Primary outcomes (6)
- measure
- Cognitive function as assessed by Functional Assessment of Cancer Therapy - Cognitive Function
- timeFrame
- at the second cycle of treatment (about day 30)
- description
- The questionnaire consists of 4 domains, including perceived cognitive impairments, comments from others, perceived cognitive abilities, and impact of quality of life. The higher the score, the better the cognitive function.
- measure
- Processing speed and executive function as assessed by Trial Making Test
- timeFrame
- at the second cycle of treatment (about day 30)
- description
- Include both trails A and B.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
\[Patient\] Inclusion Criteria: * ≥ 60 years of age * diagnosis of AML * Receive 1) low-dose cytarabine or hypomethylating agent (HMA) in combination with Venetoclax chemotherapy OR 2) low-dose cytarabine or hypomethylating agent (HMA) in combination with Venetoclax chemotherapy and any investigational drugs * have caregiver(s) willing to participate * participate in the parent study (PACT study, NCT04570709) Exclusion Criteria: * referred to hospice care \[Caregiver\] Inclusion criteria: * identified by patient as a caregiver * ≥18 years of age * speak and read English
References
Publications (0)
Data not yet available